Post

Sorry, but we now have a once-per-six-months PrEP injection with a 96% efficacy in reducing HIV infections, and the response is to limit PrEP to only pregnant women and breastfeeding mothers? What?! It's going to be much more expensive to provide lifelong treatment than work on prevention.

Saloni

@scientificdiscovery.dev

14 Feb 2025

Source:

theatlantic.comThe Erasing of American ScienceHow far can the Trump administration bend U.S. research before it breaks?

Saloni

@scientificdiscovery.dev

Sorry, my first tweet should have said we will soon have. Lenacapavir isn't approved yet for PrEP but is (was?) expected to be approved by this summer. But I'm also not sure by how the review timeline will be affected by lay-offs.

14/2/25, 10:57 pm3 reposts52 likes

Saloni

@scientificdiscovery.dev

15 Feb 2025

This thread is not about assuming the decision is about cost. It's to say that the decision doesn't hold up those grounds, when people argue that's what it's about.